Tinlarebant Phase 3 Trial Marks Major Breakthrough for STGD1
San Diego, December 1, 2025 — Belite Bio has announced positive topline results from the pivotal global Phase 3...
Phase 3 trial
Advertisement
Milvexian Phase 3 ACS Trial Discontinued After Interim Review
Dateline: November 17, 2025 — Princeton, N.J.In a significant development for anticoagulant therapy, Milvexian (also known as Librexia) —...
vTv Therapeutics Strengthens Balance Sheet for Phase 3
HIGH POINT, N.C., November 6, 2025 — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company developing innovative oral...
LB Pharmaceuticals to Present Key Data at Stifel 2025
NEW YORK, November 6, 2025 — LB Pharmaceuticals Inc. (NASDAQ: LBRX), a clinical-stage biopharmaceutical company focused on developing therapies...
Pfizer’s TUKYSA Shows Strong Benefit in First-Line HER2+ Breast Cancer
NEW YORK, Oct. 14, 2025 – Pfizer Inc. (NYSE: PFE) announced positive topline results from the Phase 3 HER2CLIMB-05...
Advertisements
Amgen’s VESALIUS-CV Trial Shows Success in Heart Disease Prevention
THOUSAND OAKS, Calif., Oct. 1, 2025 — Amgen announced that its landmark VESALIUS-CV Phase 3 trial met primary endpoints...
Larimar’s Nomlabofusp Shows Long-Term Promise in Friedreich’s Ataxia
Bala Cynwyd, Pa., September 29, 2025: Larimar Therapeutics announced positive new data from an ongoing long-term open-label study of...
ACR 2025: Phase 3 Telitacicept Results in Sjögren’s Disease
Boston, September 29, 2025 Vor Bio has announced that late-breaking Phase 3 clinical data of telitacicept in primary Sjögren’s...
Imlifidase Achieves Phase 3 Success in Kidney Transplant Trial
LUND, Sweden, Sept. 24, 2025 — Hansa Biopharma has announced that imlifidase successfully met its primary endpoint in the...
Glenmark Launches Phase 3 Global Study of Envafolimab for Lung Cancer
MUMBAI, India, September 5, 2025 — Glenmark Pharmaceuticals has announced the initiation of a multi-country Phase 3 clinical trial...
Advertisement
